DDInter624 DDInter1040
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997.
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Letrozole
Efavirenz {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Letrozole
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bifonazole
Bifonazole {u} (Compound) resembles {v} (Compound) Letrozole
Efavirenz {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Letrozole
Efavirenz {u} (Compound) causes {v} (Side Effect) Hypercholesterolaemia
Hypercholesterolaemia {u} (Side Effect) is caused by {v} (Compound) Etravirine
Etravirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Letrozole
Efavirenz {u} (Compound) causes {v} (Side Effect) Fracture
Fracture {u} (Side Effect) is caused by {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Letrozole
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Phenobarbital
Phenobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Letrozole
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Nevirapine
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Letrozole
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Letrozole
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Escitalopram
Escitalopram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Letrozole
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Letrozole (Compound)
Efavirenz (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Letrozole (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bifonazole (Compound) and Bifonazole (Compound) resembles Letrozole (Compound)
Efavirenz (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Letrozole
Efavirenz (Compound) causes Hypercholesterolaemia (Side Effect) and Hypercholesterolaemia (Side Effect) is caused by Etravirine (Compound) and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Letrozole
Efavirenz (Compound) causes Fracture (Side Effect) and Fracture (Side Effect) is caused by Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Letrozole
Efavirenz (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Phenobarbital (Compound) and Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Letrozole
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Nevirapine (Compound) and Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Letrozole
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Letrozole (Compound)
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Escitalopram (Compound) and Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Letrozole